Updated Dec. 2, 2013 at 4:45 p.m.

Premium Lock BioDelivery Sciences targets more tests for neuropathy treatment after 'positive' FDA meeting

Published: 2013-12-02 10:27:00
Updated: 2013-12-02 16:45:22

Diabetes Image 1 of 2 · Next Image…

BioDelivery Sciences invested a mix of stock and cash that could total nearly $40 million if a proposed gel to treat diabetic neuropathy pain wins FDA approval, and the company says it will proceed with further tests after a "positive" meeting with regulators....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll